Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zantac 75 EFFERdose approval dependent upon minor label changes.

This article was originally published in The Tan Sheet

Executive Summary

ZANTAC 75 EFFERDOSE FIRST OTC EFFERVESCENT H2 ANTAGONIST to be approved by FDA. Glaxo Wellcome's NDA (20-745) for the effervescent tablet form of 75 mg ranitidine cleared the agency Feb. 26. Glaxo received an "approvable" letter for the effervescent dosage form of the heartburn remedy July 8 ("The Tan Sheet" July 28, 1997, p. 8). The NDA was filed in July 1996. Warner-Lambert markets Zantac 75 under a joint venture arrangement for Glaxo's Rx-to-OTC switch products.
Advertisement

Related Content

Zantac 75 Acid Suppression "Remarkably Close" To Rx Strength - Ad
Zantac 75 Acid Suppression "Remarkably Close" To Rx Strength - Ad
Zantac 75 Acid Suppression "Remarkably Close" To Rx Strength - Ad

Topics

Advertisement
UsernamePublicRestriction

Register

PS088168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel